IL37,Tlymphocytes,NK Cells in Pathogenesis of ITP

NCT ID: NCT04482777

Last Updated: 2023-08-09

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 90 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2023-07-30
• Study Completion Date: 2023-09-01

Brief Summary

To evaluate the role of IL37 in pathogenesis of ITP and to study the relation between IL37,Tlymphocytes,NK cells in ITP

Detailed Description

Idiopathic thrombocytopenia or immune thrombocytopenia (ITP) is a hematological condition which is characterized by a low platelet count of less than 100 x 109L . Symptoms of ITP can vary but tend to be symptoms of thrombocytopenia in general, such as petechiae, purpura, mucosal bleeding and in the most severe cases fatal intracranial hemorrhage(1,2) Interleukin (IL)-37, a novel anti-inflammatory cytokine previously known as interleukin-1 family member 7 before it was renamed, has a pivotal role in the suppression of immune responses (3,4). IL-37 is widely expressed in several types of cells, tissues and organs, including peripheral blood mononuclear cells (PBMCs) (5). The major role of IL-37 is to decrease excessive inflammation in innate and adaptive immune diseases, mainly by inhibiting the expression, production and function of pro-inflammatory cytokines, including IL-1α, IL-6, tumor necrosis factor (TNF) and macrophage inflammatory protein-2. The abundance of these cytokines has been reported to increase with the silencing of endogenous IL-37 in human blood cells (3,6).Aberrant expression of IL-37 has been observed in several inflammatory and autoimmune diseases However, the role of IL-37 in ITP has remained elusive. Immune thrombocytopenia pathogenesis is a complicated process. T cell immune abnormalities are involved in ITP pathogenesis. These abnormalities include platelet auto-antigen reactive cytotoxic T cells, abnormal numbers and functions of T regulatory cells, loss of Th1/Th2 balance, megakaryocyte maturation abnormalities and abnormal T cell anergy.

Conditions

ITP

Study Design

• Observational Model Type: CASE_CONTROL
• Study Time Perspective: RETROSPECTIVE

Study Groups

ITP

Patient newly diagnosied with ITP

Corticosteriod for treated patients

Intervention Type: DRUG

Drug given to some patients with autoimmune disease

Treated

Patients with ITP recived treatment

Corticosteriod for treated patients

Intervention Type: DRUG

Drug given to some patients with autoimmune disease

Control

Healthy people

Corticosteriod for treated patients

Intervention Type: DRUG

Drug given to some patients with autoimmune disease

Interventions

Corticosteriod for treated patients

Drug given to some patients with autoimmune disease

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Patients with ITP (moderate and sever) different age group.

Exclusion Criteria

• Patients with stroke and myocardial infarction,malignant tumors or pregnancy.

• Minimum Eligible Age: 2 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Assiut University

OTHER

Sponsor Role: lead

Responsible Party

Asmaa Mohamed Elsayed

Resident physician

Responsibility Role: PRINCIPAL_INVESTIGATOR

Central Contacts

Asmaa Mohamed

Role: CONTACT

mohamedasmaa550@yahoo.com

01027575354

Marwa Mohamed

Role: CONTACT

01092288360

References

Lambert MP, Gernsheimer TB. Clinical updates in adult immune thrombocytopenia. Blood. 2017 May 25;129(21):2829-2835. doi: 10.1182/blood-2017-03-754119. Epub 2017 Apr 17.

Reference Type: BACKGROUND

PMID: 28416506 (View on PubMed)

Kistangari G, McCrae KR. Immune thrombocytopenia. Hematol Oncol Clin North Am. 2013 Jun;27(3):495-520. doi: 10.1016/j.hoc.2013.03.001.

Reference Type: BACKGROUND

PMID: 23714309 (View on PubMed)

Chen Z, Qu W, Wang HQ, Xing LM, Wu YH, Liu ZY, Zhang Y, Liu H, Dong XF, Tao JL, Shao ZH. [Relationship of Peripheral Blood IL-37 Expression with T Lymphocytes Subsets and NK Cells in Patients with Primary Immune Thrombocytopenia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2019 Aug;27(4):1201-1207. doi: 10.19746/j.cnki.issn.1009-2137.2019.04.034. Chinese.

Reference Type: BACKGROUND

PMID: 31418380 (View on PubMed)

Zhao Y, Ni X, Xu P, Liu Q, Sun T, Liu X, Ji X, Qiu J, Li J, Wang S, Han P, Peng J, Hou M, Li G. Interleukin-37 reduces inflammation and impairs phagocytosis of platelets in immune thrombocytopenia (ITP). Cytokine. 2020 Jan;125:154853. doi: 10.1016/j.cyto.2019.154853. Epub 2019 Sep 23.

Reference Type: BACKGROUND

PMID: 31557634 (View on PubMed)

Other Identifiers

Cellular immunity in ITP

Identifier Type: -

Identifier Source: org_study_id